Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT06031233 · ClinicalTrials.gov ↗ · Oncology, Infusion Reaction
|
Phase 4 |
Recruiting |
Isala |
Netherlands |
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
NCT04803994 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 3 |
Recruiting |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Germany, France, Spain, Italy, Austria, Japan |
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
NCT04996017 · ClinicalTrials.gov ↗ · Mesotheliomas Pleural
|
Phase 3 |
Recruiting |
Gruppo Oncologico Italiano di Ricerca Clinica |
Italy |
|
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
|
Phase 3 |
Recruiting |
InSightec |
USA, Canada, South Korea |
|
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
|
Phase 3 |
Recruiting |
Hoffmann-La Roche |
UK, China, France, Belgium, Poland, Canada, Mexico, Japan, South Korea, Taiwan |
|
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
|
Phase 3 |
Recruiting |
Bristol-Myers Squibb |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia |
|
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
|
Phase 3 |
Recruiting |
BioNTech SE |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Japan, South Korea, Australia, Israel |
|
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
|
Phase 3 |
Recruiting |
Gruppo Oncologico del Nord-Ovest |
Italy |
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
NCT06908993 · ClinicalTrials.gov ↗ · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
|
Phase 3 |
Recruiting |
Intergroupe Francophone de Cancerologie Thoracique |
France |
|
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
|
Phase 3 |
Recruiting |
AstraZeneca |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT07166406 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
|
Phase 3 |
Recruiting |
NRG Oncology |
Canada, Mexico |
|
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
|
Phase 3 |
Recruiting |
Boehringer Ingelheim |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517 · Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
|
Phase 3 |
Recruiting |
Boehringer Ingelheim |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia |
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644 · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
|
Phase 3 |
Recruiting |
SystImmune Inc |
USA, India, Germany, France, Spain, Italy, Poland, Czechia, Canada, South Korea, Australia |
|
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
|
Phase 2/3 |
Recruiting |
Pfizer |
USA, China, Germany, France, Spain, Italy, Japan, Taiwan, Australia |
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
NCT07285850 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma
|
Phase 2/3 |
Recruiting |
Eastern Hepatobiliary Surgery Hospital |
China |
Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)
NCT03548428 · ClinicalTrials.gov ↗ · Sarcoma, Radiosurgery
|
Phase 2 |
Recruiting |
Centre Antoine Lacassagne |
France |
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
NCT03767075 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 2 |
Recruiting |
Vall d'Hebron Institute of Oncology |
Germany, France, Spain, Italy, Netherlands, Sweden |
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
NCT04273061 · ClinicalTrials.gov ↗ · Breast Cancer, Lung Cancer, Gastrointestinal Cancer
|
Phase 2 |
Recruiting |
British Columbia Cancer Agency |
Canada |
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
NCT04341181 · ClinicalTrials.gov ↗ · Cancer, Tumors, Neoplasms
|
Phase 2 |
Recruiting |
Ulrik Lassen |
Denmark |
|
PLATFORM Study of Precision Medicine for Rare Tumors
|
Phase 2 |
Recruiting |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
China |
|
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
|
Phase 2 |
Recruiting |
University of British Columbia |
Canada, Israel |
|
Improving Public Cancer Care by Implementing Precision Medicine in Norway
|
Phase 2 |
Recruiting |
Oslo University Hospital |
Norway |
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
NCT05332561 · ClinicalTrials.gov ↗ · Early-stage Breast Cancer
|
Phase 2 |
Recruiting |
German Cancer Research Center |
Germany |
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT05528952 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 2 |
Recruiting |
Centre Hospitalier Universitaire de Besancon |
France |
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
NCT05690048 · ClinicalTrials.gov ↗ · Immunotherapy, HCC - Hepatocellular Carcinoma
|
Phase 2 |
Recruiting |
Michael Dill |
Germany |
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
NCT05733598 · Hepatocellular Carcinoma, Biliary Tract Cancer
|
Phase 2 |
Recruiting |
Replimune, Inc |
USA |
Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
NCT06133062 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable
|
Phase 2 |
Recruiting |
Chang Gung Memorial Hospital |
Taiwan |
Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
NCT06339424 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 2 |
Recruiting |
Chang Gung Memorial Hospital |
Taiwan |
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
NCT06342037 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer
|
Phase 2 |
Recruiting |
The Netherlands Cancer Institute |
Netherlands |
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
NCT06663098 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
|
Phase 2 |
Recruiting |
Gruppo Oncologico Italiano di Ricerca Clinica |
Italy |
Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
NCT06690840 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
|
Phase 2 |
Recruiting |
European Institute of Oncology |
Italy |
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
NCT07153445 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer
|
Phase 2 |
Recruiting |
Fundación GECP |
Spain |
|
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
|
Phase 2 |
Recruiting |
AbbVie |
USA, China, Germany, Spain, Italy, Belgium, Poland, Turkey, Japan, South Korea, Taiwan, Israel |
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
NCT07157969 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma
|
Phase 2 |
Recruiting |
Peking Union Medical College Hospital |
China |
|
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
|
Phase 2 |
Recruiting |
Kahr Bio Australia Pty Ltd |
USA, Australia |
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
NCT07239245 · ClinicalTrials.gov ↗ · Resectable Hepatocellular Carcinoma With High Risk of Recurrence
|
Phase 2 |
Recruiting |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
China |
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
NCT07263438 · ClinicalTrials.gov ↗ · Glioblastoma, Recurrence Tumor
|
Phase 2 |
Recruiting |
Centre Hospitalier Universitaire Vaudois |
Switzerland |
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
NCT07317414 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 2 |
Recruiting |
Peking Union Medical College Hospital |
China |
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
NCT07654400 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer
|
Phase 2 |
Recruiting |
Biokin (Shanghai) Biopharmaceutical Co., Ltd |
China |
|
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
|
Phase 1/2 |
Recruiting |
Hoffmann-La Roche |
UK, USA, Germany, France, Spain, South Korea, Taiwan, Australia, Israel |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT04802759 · Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
|
Phase 1/2 |
Recruiting |
Hoffmann-La Roche |
USA, Spain, South Korea, Australia, Israel |
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
NCT04954599 · ClinicalTrials.gov ↗ · Unspecified Adult Solid Tumor, Protocol Specific
|
Phase 1/2 |
Recruiting |
Maastricht University Medical Center |
Spain, Netherlands, Belgium |
|
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
|
Phase 1/2 |
Recruiting |
Tvardi Therapeutics, Incorporated |
USA |
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT05652686 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC)
|
Phase 1/2 |
Recruiting |
Phanes Therapeutics |
USA |
|
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
|
Phase 1/2 |
Recruiting |
Genprex, Inc |
USA |
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
NCT05765084 · ClinicalTrials.gov ↗ · Malignant Pleural Mesothelioma
|
Phase 1/2 |
Recruiting |
University Hospital, Antwerp |
Belgium |
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
NCT06157827 · ClinicalTrials.gov ↗ · Advanced Neuroendocrine Carcinoma
|
Phase 1/2 |
Recruiting |
Nanjing Leads Biolabs Co.,Ltd |
China |
|
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
|
Phase 1/2 |
Recruiting |
Daiichi Sankyo |
USA, France, Spain, Japan |
|
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
|
Phase 1/2 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, China, Germany, Spain, Italy, Poland, Turkey, South Korea, Israel |
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
NCT07407933 · Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
|
Phase 1/2 |
Recruiting |
MediLink Therapeutics (Suzhou) Co., Ltd |
UK, USA, France, Spain, Italy, Belgium, Poland |
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895 · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
|
Phase 1/2 |
Recruiting |
Boehringer Ingelheim |
UK, USA, China, Germany, France, Spain, Netherlands, Belgium, Poland, Japan, Australia |
|
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
|
Phase 1 |
Recruiting |
Hoffmann-La Roche |
UK, USA, Germany, Spain, Italy, Denmark, Poland, Canada, South Korea, Taiwan, Australia |
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
NCT05096715 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma
|
Phase 1 |
Recruiting |
Massachusetts General Hospital |
Israel |
|
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
|
Phase 1 |
Recruiting |
Chugai Pharmaceutical |
USA, Japan |
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients
NCT06012734 · ClinicalTrials.gov ↗ · Metastatic Microsatellite-stable Colorectal Cancer
|
Phase 1 |
Recruiting |
The Netherlands Cancer Institute |
Netherlands |
|
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
|
Phase 1 |
Recruiting |
Zai Lab (Shanghai) Co., Ltd |
USA, China, Spain, Israel |
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815 · Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
|
Phase 1 |
Recruiting |
KaliVir Immunotherapeutics |
USA |
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
NCT06478693 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 1 |
Recruiting |
Myeloid Therapeutics |
South Korea, Taiwan, Australia |
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
NCT06505824 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Neuroendocrine Tumors
|
Phase 1 |
Recruiting |
Biokin (Shanghai) Biopharmaceutical Co., Ltd |
China |
|
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
|
Phase 1 |
Recruiting |
GlaxoSmithKline |
UK, USA, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Israel |
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer
|
Phase 1 |
Recruiting |
SystImmune Inc |
USA |
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
NCT07190833 · ClinicalTrials.gov ↗ · Treatment-Refractory Solid Tumors
|
Phase 1 |
Recruiting |
Bionoxx Inc |
South Korea |
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
NCT05713994 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable
|
Observational |
Recruiting |
Ze-yang Ding, MD |
China |
Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
NCT05797493 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer
|
Observational |
Recruiting |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Italy |
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
NCT06323382 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab
|
Observational |
Recruiting |
Sun Yat-sen University |
China |
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
NCT06780826 · ClinicalTrials.gov ↗ · Lung Cancer, Small Cell
|
Observational |
Recruiting |
Shanghai Pulmonary Hospital, Shanghai, China |
China |
|
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
|
Observational |
Recruiting |
Hoffmann-La Roche |
UK, Spain, Italy, Belgium, Poland, Austria |
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
NCT05984511 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
|
Not applicable |
Recruiting |
Third Affiliated Hospital, Sun Yat-Sen University |
China |
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
NCT07538128 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma
|
Early Phase 1 |
Recruiting |
Huashan Hospital |
China |
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
NCT07461675 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC), Immunotherapy
|
Phase 3 |
Not yet open |
University of Geneva, Switzerland |
Switzerland |
|
A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig
|
Phase 3 |
Not yet open |
Boehringer Ingelheim |
Germany, France, Spain, Belgium, Poland, Japan |
FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
NCT05703997 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma
|
Phase 2 |
Not yet open |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Italy |
Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma
NCT07774247 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)
|
Phase 2 |
Not yet open |
CHA University |
South Korea |
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC
NCT07093762 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
|
Observational |
Not yet open |
Fuzhou General Hospital |
China |
Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma
NCT07904494 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
|
Observational |
Not yet open |
Assiut University |
Egypt |
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
NCT05185505 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatocellular Cancer
|
Phase 4 |
By invitation |
The Methodist Hospital Research Institute |
Canada |
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
NCT07620574 · Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET)
|
Phase 3 |
By invitation |
Exelixis |
USA |
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT05689671 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Metastatic
|
Phase 4 |
Active, closed |
Nikolaj Frost MD |
Germany |
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome
|
Phase 3 |
Active, closed |
National Cancer Institute (NCI) |
Germany, Mexico, Israel |
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
NCT02997228 · Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
|
Phase 3 |
Active, closed |
National Cancer Institute (NCI) |
Mexico |
|
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
|
Phase 3 |
Active, closed |
Hoffmann-La Roche |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel |
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03281954 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
|
Phase 3 |
Active, closed |
NSABP Foundation Inc |
Canada, Israel |
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
NCT03595592 · ClinicalTrials.gov ↗ · Invasive Breast Cancer
|
Phase 3 |
Active, closed |
Fondazione Michelangelo |
Germany, Spain, Italy, Austria |
|
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
|
Phase 3 |
Active, closed |
Exelixis |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia, Israel |
|
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
|
Phase 3 |
Active, closed |
Hoffmann-La Roche |
USA, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Brazil, Mexico, Japan, South Korea, Australia, Israel |
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03775265 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8
|
Phase 3 |
Active, closed |
National Cancer Institute (NCI) |
Norway |
|
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
|
Phase 3 |
Active, closed |
UNICANCER |
France, Spain, Belgium |
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002 · ClinicalTrials.gov ↗ · Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
|
Phase 3 |
Active, closed |
National Cancer Institute (NCI) |
Norway, Mexico, Japan, Egypt |
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT03977194 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic
|
Phase 3 |
Active, closed |
Intergroupe Francophone de Cancerologie Thoracique |
France |
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT04214262 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
|
Phase 3 |
Active, closed |
National Cancer Institute (NCI) |
Mexico, Israel |
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117 · Metastatic Prostate Cancer, Prostate Adenocarcinoma
|
Phase 3 |
Active, closed |
Exelixis |
UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04637594 · ClinicalTrials.gov ↗ · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma
|
Phase 3 |
Active, closed |
Alliance for Clinical Trials in Oncology |
Mexico |
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
NCT04712643 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 3 |
Active, closed |
Hoffmann-La Roche |
China, Japan |
|
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
|
Phase 3 |
Active, closed |
Hoffmann-La Roche |
UK, China, Germany, France, Spain, Italy, Belgium, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Israel, Egypt |
|
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
|
Phase 3 |
Active, closed |
Hoffmann-La Roche |
UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Czechia, Portugal, Turkey, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia |
|
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
|
Phase 3 |
Active, closed |
Hoffmann-La Roche |
China |
|
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
|
Phase 3 |
Active, closed |
Hoffmann-La Roche |
UK, USA, Germany, Spain, Italy, Belgium, Poland, Turkey, Mexico, South Korea, Taiwan |
|
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
|
Phase 3 |
Active, closed |
Hoffmann-La Roche |
China |
|
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Australia, Israel |
|
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
|
Phase 3 |
Active, closed |
Exelixis |
UK, USA, Germany, France, Spain, Belgium, Poland, Portugal, South Korea, Taiwan, Singapore, Australia |
|
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
|
Phase 3 |
Active, closed |
Hoffmann-La Roche |
UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore |
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327 · ClinicalTrials.gov ↗ · Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
|
Phase 3 |
Active, closed |
Alliance for Clinical Trials in Oncology |
Mexico |
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02839707 · ClinicalTrials.gov ↗ · Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma
|
Phase 2/3 |
Active, closed |
National Cancer Institute (NCI) |
Mexico, Israel, Egypt |
|
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2/3 |
Active, closed |
Hoffmann-La Roche |
USA, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT05063552 · ClinicalTrials.gov ↗ · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
|
Phase 2/3 |
Active, closed |
National Cancer Institute (NCI) |
Mexico |
|
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
|
Phase 2/3 |
Active, closed |
Seattle Project Corporation |
USA |
|
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
|
Phase 2/3 |
Active, closed |
AbbVie |
USA, China, France, Spain, Italy, Taiwan |
|
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
|
Phase 2 |
Active, closed |
Genentech, Inc |
UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Czechia, Norway, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
|
Phase 2 |
Active, closed |
The Netherlands Cancer Institute |
Netherlands |
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
NCT02849496 · ClinicalTrials.gov ↗ · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma
|
Phase 2 |
Active, closed |
National Cancer Institute (NCI) |
Israel |
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
NCT03141684 · ClinicalTrials.gov ↗ · Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
|
Phase 2 |
Active, closed |
National Cancer Institute (NCI) |
Israel |
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma
|
Phase 2 |
Active, closed |
ImmunityBio, Inc |
USA |
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
NCT03421288 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
|
Phase 2 |
Active, closed |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Germany, Switzerland |
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
NCT03448835 · ClinicalTrials.gov ↗ · Stomach Cancer, Gastro Esophageal Junction Cancer
|
Phase 2 |
Active, closed |
The Netherlands Cancer Institute |
Netherlands |
|
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL
|
Phase 2 |
Active, closed |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
Netherlands, Belgium |
|
Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
|
Phase 2 |
Active, closed |
Norwegian University of Science and Technology |
Netherlands, Sweden, Denmark, Switzerland, Norway |
|
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
|
Phase 2 |
Active, closed |
UNICANCER |
France |
Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT03756298 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
|
Phase 2 |
Active, closed |
National Cancer Center, Korea |
South Korea |
Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)
NCT03896074 · ClinicalTrials.gov ↗ · Non-small-cell Lung Cancer Patients
|
Phase 2 |
Active, closed |
Fondazione Ricerca Traslazionale |
Italy |
|
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
|
Phase 2 |
Active, closed |
The Netherlands Cancer Institute |
Netherlands |
ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation
NCT04082897 · ClinicalTrials.gov ↗ · CLL Transformation
|
Phase 2 |
Active, closed |
Niguarda Hospital |
Italy, Switzerland |
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy
NCT04138628 · ClinicalTrials.gov ↗ · Bladder Cancer, Bladder Cancer, Metastatic
|
Phase 2 |
Active, closed |
Jørgen Bjerggaard Jensen |
Denmark |
|
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer
|
Phase 2 |
Active, closed |
Spanish Oncology Genito-Urinary Group |
Spain |
|
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 |
Active, closed |
Genentech, Inc |
USA |
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
NCT04310020 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
|
Phase 2 |
Active, closed |
National Cancer Institute (NCI) |
Mexico, Israel |
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
NCT04334941 · ClinicalTrials.gov ↗ · Extensive Stage Lung Small Cell Carcinoma
|
Phase 2 |
Active, closed |
National Cancer Institute (NCI) |
Mexico, Israel |
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
NCT04356729 · ClinicalTrials.gov ↗ · Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma
|
Phase 2 |
Active, closed |
F. Stephen Hodi, MD |
Israel |
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
NCT04458922 · ClinicalTrials.gov ↗ · Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma
|
Phase 2 |
Active, closed |
National Cancer Institute (NCI) |
Canada |
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
NCT04563338 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic, Liver Metastases
|
Phase 2 |
Active, closed |
University Health Network, Toronto |
Canada |
|
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
|
Phase 2 |
Active, closed |
Hoffmann-La Roche |
UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel, Egypt |
|
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
|
Phase 2 |
Active, closed |
Swiss Cancer Institute |
Switzerland |
|
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
|
Phase 2 |
Active, closed |
Fondazione Melanoma Onlus |
Italy |
|
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
|
Phase 2 |
Active, closed |
University Hospital, Montpellier |
France |
|
Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer
|
Phase 2 |
Active, closed |
SOLTI Breast Cancer Research Group |
Spain |
|
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
|
Phase 2 |
Active, closed |
Hoffmann-La Roche |
UK, USA, Germany, France, Spain, Italy, Switzerland, Czechia, Turkey, Canada, South Korea, Australia |
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
NCT04962126 · ClinicalTrials.gov ↗ · Follicular Lymphoma
|
Phase 2 |
Active, closed |
Olivia Newton-John Cancer Research Institute |
Australia |
|
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
|
Phase 2 |
Active, closed |
Hoffmann-La Roche |
China |
|
Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin
|
Phase 2 |
Active, closed |
AIO-Studien-gGmbH |
Germany |
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
NCT05152472 · ClinicalTrials.gov ↗ · Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
|
Phase 2 |
Active, closed |
Centre Leon Berard |
France |
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
NCT05174650 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma
|
Phase 2 |
Active, closed |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Germany |
|
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
|
Phase 2 |
Active, closed |
Shanghai Henlius Biotech |
USA, Egypt |
A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
NCT05470595 · ClinicalTrials.gov ↗ · Large Cell Neuroendocrine Carcinoma of the Lung
|
Phase 2 |
Active, closed |
Technische Universität Dresden |
Germany |
|
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
|
Phase 2 |
Active, closed |
Hoffmann-La Roche |
UK, USA, China, Germany, France, Spain, Italy, Denmark, Poland, Turkey, Brazil, Mexico, South Korea, Australia |
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
NCT05781308 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
|
Phase 2 |
Active, closed |
Intergroupe Francophone de Cancerologie Thoracique |
France |
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
NCT05825625 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer
|
Phase 2 |
Active, closed |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Germany |
|
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
|
Phase 2 |
Active, closed |
Genentech, Inc |
UK, USA, Germany, France, Spain, Netherlands, Belgium, Sweden, Canada, South Korea |
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
NCT06003621 · ClinicalTrials.gov ↗ · Solid Tumor, Adult
|
Phase 2 |
Active, closed |
Omico |
Australia |
|
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
|
Phase 2 |
Active, closed |
Genentech, Inc |
USA, Israel |
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
NCT04440735 · Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
|
Phase 1/2 |
Active, closed |
Kahr Medical |
USA |
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
NCT04471727 · ClinicalTrials.gov ↗ · Small-Cell Lung Cancer, Neuroendocrine Carcinoma
|
Phase 1/2 |
Active, closed |
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
USA |
|
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
|
Phase 1/2 |
Active, closed |
Hoffmann-La Roche |
USA, China, France, South Korea, Taiwan, Israel |
|
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
|
Phase 1/2 |
Active, closed |
Novartis Pharmaceuticals |
UK, USA, China, Germany, France, Spain, Austria, Czechia, Canada, South Korea, Singapore, Israel |
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
NCT05286801 · ClinicalTrials.gov ↗ · Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma
|
Phase 1/2 |
Active, closed |
National Cancer Institute (NCI) |
Canada, Australia |
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
NCT05300282 · ClinicalTrials.gov ↗ · Relapsed or Refractory Hodgkin's Lymphoma
|
Phase 1/2 |
Active, closed |
Fondazione Italiana Linfomi - ETS |
Italy |
|
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
|
Phase 1/2 |
Active, closed |
FBD Biologics Limited |
China |
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
NCT07280377 · ClinicalTrials.gov ↗ · Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic
|
Phase 1/2 |
Active, closed |
Oncolytics Biotech |
Germany |
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
NCT02862275 · ClinicalTrials.gov ↗ · Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
|
Phase 1 |
Active, closed |
National Cancer Institute (NCI) |
Canada |
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960 · Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
|
Phase 1 |
Active, closed |
Exelixis |
UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Australia |
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166 · Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma
|
Phase 1 |
Active, closed |
Exelixis |
UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Czechia, Australia |
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883 · Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
|
Phase 1 |
Active, closed |
Amgen |
UK, USA, Germany, Spain, Italy, Netherlands, Belgium, Austria, Canada, Japan, South Korea, Taiwan, Australia |
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT04449874 · Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
|
Phase 1 |
Active, closed |
Genentech, Inc |
UK, USA, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Norway, Canada, Brazil, South Korea, Australia, Israel |
A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
NCT04808245 · ClinicalTrials.gov ↗ · Newly Diagnosed H3-mutated Glioma
|
Phase 1 |
Active, closed |
German Cancer Research Center |
Germany |
Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.
NCT05097911 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma
|
Phase 1 |
Active, closed |
National University Hospital, Singapore |
Singapore |
|
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
|
Phase 1 |
Active, closed |
Amgen |
USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Switzerland, Canada, Japan, South Korea, Taiwan, Australia, Israel |
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
NCT05546879 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 1 |
Active, closed |
University Hospital, Grenoble |
France |
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004 · Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC
|
Phase 1 |
Active, closed |
Genentech, Inc |
USA, Spain, Netherlands, Belgium, Canada, South Korea, Taiwan, Australia |
|
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
|
Phase 1 |
Active, closed |
RayzeBio, Inc |
USA |
|
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
|
Phase 1 |
Active, closed |
Glenmark Specialty S.A |
USA, India |
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441 · Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
|
Phase 1 |
Active, closed |
Genentech, Inc |
UK, USA, Canada, Singapore, Australia |
|
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
|
Phase 1 |
Active, closed |
Boehringer Ingelheim |
USA, Germany, France, Spain, Belgium, Poland, Switzerland, Japan |
|
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
|
Phase 1 |
Active, closed |
Hoffmann-La Roche |
USA, Canada, South Korea |
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
NCT05525858 · ClinicalTrials.gov ↗ · Solid Tumor, Advanced Solid Tumor, Metastatic Cancer
|
Observational |
Active, closed |
Seoul National University Bundang Hospital |
South Korea |
|
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
|
Observational |
Active, closed |
Bayer |
USA, China, France, Spain, Italy, Brazil, South Korea, Taiwan |
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
NCT04180072 · ClinicalTrials.gov ↗ · Carcinoma, Hepatocellular
|
Not applicable |
Active, closed |
National Health Research Institutes, Taiwan |
China, Taiwan |